文献速递复苏、休克与脓毒症创伤与烧伤重症综合管理与镇静镇痛

新型人糖皮质激素受体变异体G459V对类固醇呈高反应性

A Novel Human Glucocorticoid Receptor Variant, G459V, is Hyperactive in Response to Steroids.
PubMed 文献 · Shock · 2021-01-01
一句话结论烧伤患者中发现hGR变异体G459V,对氢化可的松反应超30倍,且对RU486反常激活,可能解释应激与激素反应差异。

研究从烧伤面积≥20%的住院患者入院时及此后每两周采血,鉴定hGR变异体。发现G1376T SNP导致DNA结合域G459V氨基酸改变。报告基因实验显示,氢化可的松处理下G459V活性超过参考hGRα 30倍;单用RU486(米非司酮)时G459V活性显著增加;RU486联合氢化可的松时G459V活性被抑制但仍高于单用RU486。共转染模拟异构体相互作用时活性接近hGRα。G459V可能改变个体对应激和激素治疗的反应。

要点

  • 在烧伤面积≥20%的住院患者中鉴定出hGR G1376T SNP,导致DNA结合域谷氨酰胺→缬氨酸(G459V)改变。
  • 报告基因实验中,氢化可的松处理下G459V活性超过参考hGRα 30倍以上。
  • 单用hGR拮抗剂RU486(米非司酮)时G459V活性显著增加,与预期拮抗效应相反。
  • RU486联合氢化可的松时G459V活性被抑制,但仍高于单用RU486。
  • 共转染hGRα与G459V模拟异构体相互作用时,活性更接近hGRα而非G459V。

适用人群与场景

  • 烧伤面积至少20%总体表面积(TBSA)的住院患者,入院时及此后每两周采血用于hGR变异体鉴定。
  • 原文未提及急诊/ICU/院前场景的适用人群,也未提及排除人群。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为实验室报告基因实验,样本来自烧伤面积≥20% TBSA的住院患者系列采血,原文未提及样本量及中心数。
  • 鉴定出G1376T SNP导致hGR DNA结合域G459V氨基酸改变。
  • 氢化可的松处理下G459V活性超过参考hGRα 30倍以上。
  • 单用RU486(米非司酮)时G459V活性显著增加;RU486联合氢化可的松时G459V活性被抑制但仍高于单用RU486。
  • 共转染hGRα与G459V模拟异构体相互作用时,活性更接近hGRα而非G459V。

证据类型、等级与局限

  • 证据类型为实验室研究(报告基因实验),原文未给出证据等级或推荐强度。
  • 局限:原文未提及样本量、中心数及统计细节;为体外功能实验,需进一步临床验证。

对床旁实践的改变

  • 原文提示部分hGR变异体可能改变个体对应激和激素治疗的反应,但未提供可直接改变急诊/ICU床旁决策的推荐。
  • 原文未提及适用与不适用人群的具体建议。
  • 常见陷阱:不能将体外报告基因实验的G459V活性数据(如超过hGRα 30倍)直接用作临床激素剂量或疗效判断依据。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

A potential cause of the variable response to injury and sepsis is the variability of a patient's human glucocorticoid receptor (hGR) profile. To identify hGR variants, blood samples were collected on admission and biweekly thereafter from hospitalized patients who sustained at least a 20% total body surface area burn injury. A hyperactive G1376T single-nucleotide polymorphism (SNP) isoform was identified. This SNP led to a single amino acid change of glutamine to valine at site 459, "G459V," in the DNA-binding domain. The isoform's activity was tested in a reporter assay after treatment with steroids, the hGR antagonist RU486 (mifepristone) alone, or RU486 followed by steroids. When treated with hydrocortisone, the hGR G459V isoform had a hyperactive response; its activity was over 30 times greater than the reference hGRα. Unexpectedly, G459V had significantly increased activity when treated with the hGR antagonist RU486. With the combination of both RU486 and hydrocortisone, G459V activity was repressed, but greater than that of RU486 alone. Finally, when hGRα was cotransfected with G459V to simulate isoform interaction, the activity was closer to that of the hGRα profile than the G459V isoform. The unique activity of the G459V isoform shows that some variants of hGR have the potential to alter a person's response to stress and steroid treatment and may be a factor as to why mitigating the clinical response to sepsis and other stressors has been so elusive.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Grigsby MJ, Green TL, Lim D, et al. A Novel Human Glucocorticoid Receptor Variant, G459V, is Hyperactive in Response to Steroids. Shock. 2021. PMID: 34276041. doi:10.1097/SHK.0000000000001729

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。